Dubosq-Lebaz Maxime, Fels Audrey, Chatellier Gilles, Gouëffic Yann
Vascular & Endovascular Surgery, Aortic Center, Institut Coeur-Poumon, CHU de Lille, Lille, France.
Clinical Research Department, Groupe Hospitalier Paris St Joseph, Paris, France.
J Endovasc Ther. 2025 Jun;32(3):593-604. doi: 10.1177/15266028231202709. Epub 2023 Sep 30.
Indications for endovascular treatment of femoropopliteal (FP) lesions have steadily increased over the past decade. Accordingly, the number of devices has also increased but the choice of the best endovascular treatment remains to be defined. The aim of this meta-analysis was to summarize all studies investigating endovascular treatment of FP lesions greater than 150 mm from 2010 to 2021.
Articles were searched using PubMed, Scopus, and Cochrane. Included studies were randomized controlled trials (RCTs), cohort studies, and case series (prospective and retrospective) that evaluated any endovascular procedure in patients with long FP lesions classified TASC (Trans-Atlantic Inter-Society Consensus document II on management of peripheral arterial disease) C and/or D, and a mean length 150 mm, primary outcome had to be the 1-year primary patency. Overall estimate of primary patency, secondary patency, and freedom from target lesion revascularization (TLR) at 1 year depending on the different devices were investigated. The meta-analysis was conducted following the requirements of the MOOSE (Meta-analysis of Observational Studies in Epidemiology) checklist.
Forty-four papers comprising 4847 patients and 5282 treated limbs were included. Mean lesions length ranged from 150.5 to 330 mm. The pooled 1-year primary and secondary patencies, and freedom from TLR rates were 0.71 (95% CI: 0.67-0.74), 0.87 (95% CI: 0.83-0.91), and 0.79 (95% CI: 0.74-0.84), respectively. Primary permeability at 1 year were 0.68 (95% CI: 0.62-0.73), 0.67 (95% CI: 0.60-0.74), 0.74 (95% CI: 0.64-0.84), and 0.83 (95% CI: 0.78-0.88) for bare metal stents, covered stents (CSs), drug-eluting stents, and drug-coated balloons (DCBs), respectively. Lesions treated with DCB had the highest 1-year primary patency rate.
At 1-year, endovascular procedures for FP lesions greater than 150 mm obtain satisfactory results. High primary patency rates were obtained with drug-coated devices, while CSs obtained less favorable results. Randomized studies comparing different devices in the treatment of long FP lesions remain necessary to determine the most optimal approach for the management of these patients.Clinical ImpactThis paper highlights on the one hand the satisfactory results of endovascular treatment on complex femoropopliteal lesions formerly reserved for conventional surgery. On the other hand, among the available devices, paclitaxel-eluting devices seem to show superior results which should make them recommended as first-line treatment.
在过去十年中,股腘(FP)病变血管内治疗的适应证稳步增加。相应地,治疗器械的数量也有所增加,但最佳血管内治疗方法的选择仍有待确定。本荟萃分析的目的是总结2010年至2021年间所有关于治疗长度超过150 mm的FP病变的血管内治疗研究。
通过PubMed、Scopus和Cochrane检索文献。纳入的研究为随机对照试验(RCT)、队列研究和病例系列(前瞻性和回顾性),这些研究评估了TASC(《跨大西洋两岸血管外科学会关于外周动脉疾病管理的共识文件II》)C和/或D级、平均长度≥150 mm的长FP病变患者的任何血管内治疗程序,主要结局必须是1年的主要通畅率。研究了根据不同器械在1年时主要通畅率、次要通畅率和免于靶病变血管重建(TLR)的总体估计值。本荟萃分析按照MOOSE(流行病学观察性研究的荟萃分析)清单的要求进行。
纳入了44篇论文,共4847例患者和5282条接受治疗的肢体。平均病变长度在150.5至330 mm之间。汇总的1年主要和次要通畅率以及免于TLR率分别为0.71(95%CI:0.67 - 0.74)、0.87(95%CI:0.83 - 0.91)和0.79(95%CI:0.74 - 0.84)。裸金属支架、覆膜支架(CS)、药物洗脱支架和药物涂层球囊(DCB)在1年时的主要通畅率分别为0.68(95%CI:0.62 - 0.73)、0.67(95%CI:0.60 - 0.74)、0.74(95%CI:0.64 - 0.84)和0.83(95%CI:0.78 - 0.88)。接受DCB治疗的病变1年主要通畅率最高。
在1年时,针对长度超过150 mm的FP病变的血管内治疗程序取得了令人满意的结果。药物涂层器械获得了较高的主要通畅率,而CS的效果较差。仍有必要进行比较不同器械治疗长FP病变的随机研究,以确定这些患者管理的最佳方法。临床影响本文一方面强调了血管内治疗对以前需行传统手术的复杂股腘病变的满意效果。另一方面,在现有器械中,紫杉醇洗脱器械似乎显示出更好的效果,这使其应被推荐为一线治疗方法。